颅内间叶性肿瘤FET::CREB融合阳性:81例整合分析
本研究对81例颅内间叶性肿瘤FET::CREB融合阳性(ICMT)进行甲基化谱分析,其中61例新检测、20例来自公开数据。结果显示ICMT具有相对独特的甲基化特征,并确认两个甲基化亚类:亚类A占85%(69例),中位年龄26岁;亚类B占15%(12例),中位年龄15岁,且无进展生存期更短(P < 0.01)。基因表达分析显示CREM基因显著过表达,与融合类型无关。
要点
- ICMT可分为两个甲基化亚类,亚类B无进展生存期更短。
- 亚类A中位年龄26岁,亚类B中位年龄15岁。
- CREM基因在ICMT中显著过表达,与融合类型无关。
核心结论
- ICMT是一种易复发的CNS间叶性肿瘤,具有两个预后相关的甲基化亚类,需与表观遗传和组织学相关肿瘤鉴别。
- ICMT中CREM基因显著过表达,且不依赖于融合类型。
研究设计与样本
- 研究纳入81例ICMT病例,包括61例新检测病例和20例来自公开数据的病例,进行甲基化谱分析并记录临床病理和基因组数据。
主要发现
- ICMT与相关肿瘤相比显示出相对独特的甲基化特征。
- 在65例记录融合类型的病例中,融合包括EWSR1::ATF1(25例)、EWSR1::CREB1(12例)、EWSR1::CREM(21例)、FUS::CREM(3例)和SMARCA2::CREM(4例)。
- 亚类A占85%(69例),中位年龄26岁;亚类B占15%(12例),中位年龄15岁。
- 亚类B的无进展生存期更短(P < 0.01)。
- 与脑膜瘤或更广泛CNS肿瘤相比,ICMT中CREM显著过表达,与融合类型无关。
关键数值与推荐
- 亚类A:69例(85%),中位年龄26岁。
- 亚类B:12例(15%),中位年龄15岁,无进展生存期更短(P < 0.01)。
- 融合类型分布:EWSR1::ATF1 25例,EWSR1::CREB1 12例,EWSR1::CREM 21例,FUS::CREM 3例,SMARCA2::CREM 4例(共65例有记录)。
临床怎么用
- 对ICMT应进行甲基化分型以区分亚类A和B,亚类B需更密切随访。
- 诊断时需将ICMT与表观遗传及组织学相关肿瘤鉴别,避免误诊。
- CREM过表达可作为ICMT的辅助诊断标志,与融合类型无关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intracranial mesenchymal tumors, FET::CREB fusion-positive (ICMT), show fusions involving FET RNA-binding protein family genes (EWSR1 or FUS) and CREB family of transcription factors (ATF1, CREB1, or CREM). The methylation signature(s), gene expression characteristics, and clinical behavior of this important tumor type require further characterization. METHODS: We study the methylation profiles of 81 ICMT cases (61 newly profiled cases and 20 cases from publicly available sources). Clinicopathologic and genomic data were recorded for each case when available. RESULTS: ICMT showed a relatively distinct methylation signature compared to related tumors. Among the 65 cases where fusion types were documented, the identified fusions included EWSR1::ATF1 (25 cases), EWSR1::CREB1 (12 cases), EWSR1::CREM (21 cases), FUS::CREM (3 cases), and SMARCA2::CREM (4 cases). We confirmed the prior description of 2 distinct subgroups of ICMT (subclasses A and B). The majority of the cases belonged to subclass A (n = 69; 85%), which showed a higher median age compared to subclass B patients (26 years vs. 15 years). Subclass B cases (n = 12; 15%) showed shorter progression-free survival (P < 0.01). Gene expression analysis of ICMT showed key overexpressed markers in ICMT, with significant CREM overexpression regardless of fusion type, when compared to either meningioma alone or a larger group of CNS tumors. CONCLUSIONS: This work provides further characterization of ICMT as an important CNS mesenchymal neoplasm that is prone to tumor recurrence, showing 2 prognostically relevant methylation subclasses and warranting diagnostic distinction from other epigenetically and histologically related tumors. ICMTs show substantial overexpression of the CREM gene, independent of fusion type.
引用
- Rajan S, Chung HJ, Wu Z, et al. Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases. Neuro Oncol. 2026. PMID: 41569358. doi:10.1093/neuonc/noag001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。